Compare ESRT & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESRT | STTK |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 836.1M | 683.8M |
| IPO Year | 2012 | 2020 |
| Metric | ESRT | STTK |
|---|---|---|
| Price | $4.72 | $7.43 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 7 |
| Target Price | $6.35 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 1.9M | 963.1K |
| Earning Date | 04-29-2026 | 05-01-2026 |
| Dividend Yield | ★ 2.49% | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $768,270,000.00 | $1,000,000.00 |
| Revenue This Year | $4.26 | N/A |
| Revenue Next Year | $1.52 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.05 | N/A |
| 52 Week Low | $4.61 | $0.80 |
| 52 Week High | $8.07 | $8.33 |
| Indicator | ESRT | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 36.97 | 54.34 |
| Support Level | N/A | $5.87 |
| Resistance Level | $5.85 | $7.75 |
| Average True Range (ATR) | 0.18 | 0.48 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 13.41 | 50.00 |
Empire State Realty Trust Inc is a real estate investment trust (REIT) that owns and operates office, retail, and multifamily properties located in New York City, prominently in Manhattan. Its portfolio includes office and retail space as well as residential units. The company's objective is to maximize cash flow and total returns to its shareholders and to increase the value of the properties. Its reportable segments consist of a real estate segment and an Observatory segment. The majority of revenue is derived from the Real Estate segment, which includes all activities related to the ownership, management, operation, acquisition, redevelopment, repositioning and disposition of its traditional real estate assets.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.